Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CGEN: Collagen Aesthetics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: JoeinIowa who wrote (2)	12/2/2000 10:36:50 AM
From: JoeinIowa	Read Replies (1) \| Respond to of 8

Thursday September 14, 8:12 am Eastern Time Press Release Compugen Introduces Gencarta Comprehensive Platform of Annotated Genome, Transcriptome and Proteome Databases Gencarta(TM) utilizes Compugen's LEADS transcriptome technology for the enhancement of drug target discovery MIAMI BEACH, Fla.--(BW HealthWire)--Sept. 14, 2000-- Compugen Ltd. (Nasdaq:CGEN - news), announced today at the annual Genome Sequencing and Analysis Conference, Miami Beach, Florida, the launch of Gencarta(TM), a comprehensive platform providing access to Compugen's proprietary annotated genome, transcriptome and proteome databases. Biologists and other life science researchers will be able to explore these annotated databases and focus in on genes of interest, helping them filter the mass of genomic and expressed information and better understand complex biological processes. Gencarta(TM) will provide researchers with access to Compugen's proprietary LEADS transcriptome database. The periodic application of LEADS analysis and data mining tools to various public and non-public databases result in one comprehensive data source, which includes tens of thousands of predicted genes and splice variants, putative cSNPs and annotated genomic information. LEADS gene predictions have been tested in hundreds of cases and verified with a success rate of over 90% in Compugen's molecular biology laboratory. ``In the post-genomic era, scientists are in need of a tool that will analyze and deliver the vast quantity of available information and diverse databases in a comprehensive and integrated manner,'' said Dr. Mor Amitai, President and Chief Executive Officer, Compugen. ``We believe that Gencarta will enhance genomic research and discovery and will meaningfully contribute to the drug development process.'' Using Gencarta intuitive viewers, users will be able to query and browse the genome, with access to data of interest on several levels. The genomic level includes information concerning genes and pseudogenes, repeats, CpG islands, SNPs, enhancers, and promoters. The transcript level includes information regarding splice variants, aligned ESTs and mRNAs. Each splice variant is then further annotated with information about homologues, SAGE-based expression profiles, open reading frames, sequence translation and detailed domain summaries. Gencarta is expected to be commercially available for corporate installation at high throughput laboratories in the first quarter of 2001. It will be available on subscription bases with periodic updates. About Compugen Compugen (www.cgen.com) is a pioneer in the field of computational genomics and proteomics. Based on a unique combination of advanced mathematics, computer science and molecular biology, Compugen develops proprietary comprehensive platforms to improve and accelerate life science research. These platforms are provided to leading organizations such as Pfizer, Human Genome Sciences, Inc. and the U.S. Patent and Trademark Office to significantly enhance and accelerate their research efforts in the discovery of drugs, therapeutics, diagnostics and agricultural products and in their general understanding of biological data of all types. Through its LabOnWeb.com Web site, Compugen has begun to provide certain components of its platforms to individual molecular biologists and other life scientists worldwide. In addition, Compugen has recently established its Novel Genomics division to commercialize, mainly through licensing arrangements, some of the genes and proteins that it discovers in its own research efforts. This press release contains ``forward-looking statements.'' These statements include expectations as to Compugen's expected commercial availability of Gencarta, and other statements that include words like ``may,'' ``expects,'' ``believes,'' and ``intends,'' and that describe opinions about future events. These forward-looking statements are subject to risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially difference from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; the ability to implement technological improvements; the ability of Compugen to obtain and retain customers. These and other factors are identified and more fully explained under the heading ``Risk Factors'' in our Registration Statement on Form F-1 filed with the Securities and Exchange Commission. -------------------------------------------------------------------------------- Contact: Compugen Ltd. Tsipi Haitovsky, +972-3-7658120 tsipi@cgen.com Email this story - View most popular stories emailed